Clinical Trial: Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Treatment of Chronic Central Serous Chorioretinopathy With Open-label Anecortave Acetate

Brief Summary: Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy

Detailed Summary:

Central serous chorioretinopathy (CSC) is a disease of the macula characterized by loss of vision from exudation of fluid under the retina localized to the posterior pole. Acute central serous chorioretinopathy (CSC) has been defined as an idiopathic detachment of the neurosensory retina in the macular region associated with a focal leak at the level of the retinal pigment epithelium on fluorescein angiography. This area of leakage usually corresponds to a defect in retinal pigment epithelium (RPE). An acute episode of CSC usually resolves within 3 months from the time of onset with almost total restoration of the visual acuity.

However, in a more severe form of the disease, chronic central serous chorioretinopathy, there is diffuse decompensation of the RPE, recurrent retinal detachments, and progressive loss of visual acuity. Indocyanine green angiography shows diffuse hyperpermeability of the choriocapillaris layer. This chronic form of CSC is usually bilateral, and often causes severe vision loss and impaired quality of life for the patient. Chronic central serous chorioretinopathy can be defined on the basis of two factors: 1) persistence of the detachment for more than 6 months and 2) chronic recurrent acute detachments with widespread decompensation of the retinal pigment epithelium.

The standard of care for acute CSC is observation for a period of up to 3 months. If there is no complete resolution of the retinal detachment by 3 months, focal laser photocoagulation therapy may be used to treat the area of leakage. This treatment is usually effective in stopping leakage of fluid under the retina and causing resolution of the detachment. However, laser photocoagulation therapy is not beneficial in the treatment of chronic CSC because there is not a single easily identifiable point of leakage but rather diffuse disease
Sponsor: Manhattan Eye, Ear & Throat Hospital

Current Primary Outcome: To investigate the use of Anecortave Acetate in patients with chronic central Chorioretinopathy [ Time Frame: 24 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome: •Mean change in ETDRS Visual Acuity at 4 meters compared to baseline •Mean change in central retinal thickness as measured by OCT . -Change in leakage area seen during fluorescein angiography and ICG [ Time Frame: 24 months ]

Original Secondary Outcome: Same as current

Information By: Manhattan Eye, Ear & Throat Hospital

Dates:
Date Received: June 20, 2007
Date Started: May 2007
Date Completion:
Last Updated: October 24, 2012
Last Verified: October 2012